Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	3/9/2007 1:23:22 AM
	Read Replies (1) of 10280

Sepracor "outperform" Thursday, March 08, 2007 5:28:25 AM ET Credit Suisse NEW YORK, March 8 (newratings.com) - Analyst M Goodman of Credit Suisse maintains his "outperform" rating on Sepracor Inc (SEPR.NAS). The target price is set to $65. In a research note published yesterday, the analyst mentions that the company is expected to receive double-digit royalties going forward, if the Levocertirizine drug, which is partnered with Sanofi, receives full FDA approval. Credit Suisse expects the company's share price to appreciate significantly during the year. The alteration in the CMS reimbursement for Xopenex is likely to either have a marginal adverse impact or no impact at all on the company’s performance going forward, Credit Suisse adds.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next